Journal List > Korean J Gastroenterol > v.73(5) > 1125195

Kim and Jung: Renal and Urinary Manifestations of Inflammatory Bowel Disease

Abstract

The incidence of inflammatory bowel disease (IBD) is increasing rapidly and extra-intestinal manifestations in IBD are also increasing. The prevalence of renal and urinary involvement in IBD ranges from 4–23%. Nephrolithiasis is the most common urinary complication in IBD patients. Parenchymal renal disease is rare but has been well documented and presents most commonly as glomerulonephritis or tubulointerstitial nephritis. The overall morbidity of IBD-related renal manifestations is significant. Therefore, a high index of clinical suspicion and optimal monitoring of the renal function are needed for the early diagnosis and prevention of IBD-related renal manifestations and complications.

Figures and Tables

Fig. 1

Diagnostic approach of renal and urinary manifestations in patients with inflammatory bowel disease. 5-ASA, 5-aminosalicylate; CsA, Cyclosporin A; TNFα, tumor necrosis factor alpha; eGFR, estimated glomerular filtration rate; IBD, inflammatory bowel disease.

kjg-73-260-g001
Table 1

Renal and Urinary Manifestations of Inflammatory Bowel Disease

kjg-73-260-i001

C3, complement 3.

Table 2

Drug-associated Nephrotoxicity in Inflammatory Bowel Disease

kjg-73-260-i002

TNF-α, tumor necrosis factor-alpha.

Notes

Financial support None.

Conflict of interest None.

References

1. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001; 96:1116–1122.
crossref
2. Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Díaz-Rubio M. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis. Med Clin (Barc). 2005; 125:297–300.
3. Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis. Expert Rev Gastroenterol Hepatol. 2019; 13:307–317.
crossref
4. Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol. 1998; 93:504–514.
crossref
5. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008; 14:542–549.
crossref
6. Ng SC, Tang W, Leong RW, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut. 2015; 64:1063–1071.
7. Corica D, Romano C. Renal involvement in inflammatory bowel diseases. J Crohns Colitis. 2016; 10:226–235.
crossref
8. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci. 1999; 44:1–13.
9. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006; 12:4819–4831.
crossref
10. Sato H, Umemura K, Yamamoto T, Sato H. Interstitial nephritis associated with ulcerative colitis in monozygotic twins. BMJ Case Rep. 2017; 2017:bcr2016218346.
crossref
11. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005; 11:7227–7236.
crossref
12. Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17:1034–1045.
crossref
13. Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol. 2014; 9:265–270.
crossref
14. Shield DE, Lytton B, Weiss RM, Schiff M Jr. Urologic complications of inflammatory bowel disease. J Urol. 1976; 115:701–706.
crossref
15. Andersson H, Bosaeus I, Fasth S, Hellberg R, Hultén L. Cholelithiasis and urolithiasis in Crohn's disease. Scand J Gastroenterol. 1987; 22:253–256.
crossref
16. Parks JH, Worcester EM, O'Connor RC, Coe FL. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int. 2003; 63:255–265.
crossref
17. Kane S. Urogenital complications of Crohn's disease. Am J Gastroenterol. 2006; 101:12 Suppl. S640–S643.
crossref
18. Gkentzis A, Kimuli M, Cartledge J, Traxer O, Biyani CS. Urolithiasis in inflammatory bowel disease and bariatric surgery. World J Nephrol. 2016; 5:538–546.
crossref
19. Fisang C, Anding R, Müller SC, Latz S, Laube N. Urolithiasis--an interdisciplinary diagnostic, therapeutic and secondary preventive challenge. Dtsch Arztebl Int. 2015; 112:83–91.
20. Primas C, Novacek G, Schweiger K, et al. Renal insufficiency in IBD--prevalence and possible pathogenetic aspects. J Crohns Colitis. 2013; 7:e630–e634.
21. Ambruzs JM, Larsen CP. Renal manifestations of inflammatory bowel disease. Rheum Dis Clin North Am. 2018; 44:699–714.
crossref
22. Allison MJ, Cook HM, Milne DB, Gallagher S, Clayman RV. Oxalate degradation by gastrointestinal bacteria from humans. J Nutr. 1986; 116:455–460.
crossref
23. McConnell N, Campbell S, Gillanders I, Rolton H, Danesh B. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. 2002; 89:835–841.
crossref
24. Cury DB, Moss AC, Schor N. Nephrolithiasis in patients with inflammatory bowel disease in the community. Int J Nephrol Renovasc Dis. 2013; 6:139–142.
crossref
25. Varda BK, McNabb-Baltar J, Sood A, et al. Urolithiasis and urinary tract infection among patients with inflammatory bowel disease: a review of US emergency department visits between 2006 and 2009. Urology. 2015; 85:764–770.
crossref
26. Hubert D, Beaufils M, Meyrier A. Immunoglobulin A glomerular nephropathy associated with inflammatory colitis. Apropos of 2 cases. Presse Med. 1984; 13:1083–1085.
27. Trimarchi HM, Iotti A, Iotti R, Freixas EA, Peters R. Immunoglobulin A nephropathy and ulcerative colitis. A focus on their pathogenesis. Am J Nephrol. 2001; 21:400–405.
28. Takemura T, Okada M, Yagi K, Kuwajima H, Yanagida H. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications. Pediatr Nephrol. 2002; 17:863–866.
crossref
29. Forshaw MJ, Guirguis O, Hennigan TW. IgA nephropathy in association with Crohn's disease. Int J Colorectal Dis. 2005; 20:463–465.
crossref
30. Onime A, Agaba EI, Sun Y, et al. Immunoglobulin A nephropathy complicating ulcerative colitis. Int Urol Nephrol. 2006; 38:349–353.
crossref
31. Lee JM, Lee KM, Kim HW, et al. Crohn's disease in association with IgA nephropathy. Korean J Gastroenterol. 2008; 52:115–119.
32. Moayyedi P, Fletcher S, Harnden P, Axon AT, Brownjohn A. Mesangiocapillary glomerulonephritis associated with ulcerative colitis: case reports of two patients. Nephrol Dial Transplant. 1995; 10:1923–1924.
33. Fornaciari G, Maccari S, Borgatti PP, et al. Nephrotic syndrome from 5-ASA for ulcerative colitis? Complicated by carcinoma of the colon and sclerosing cholangitis. J Clin Gastroenterol. 1997; 24:37–39.
34. Firwana BM, Hasan R, Chalhoub W, et al. Nephrotic syndrome after treatment of Crohn's disease with mesalamine: case report and literature review. Avicenna J Med. 2012; 2:9–11.
crossref
35. Casella G, Perego D, Baldini V, Monti C, Crippa S, Buda CA. A rare association between ulcerative colitis (UC), celiac disease (CD), membranous glomerulonephritis, leg venous thrombosis, and heterozygosity for factor V Leiden. J Gastroenterol. 2002; 37:761–762.
crossref
36. Warling O, Bovy C, Coïmbra C, Noterdaeme T, Delwaide J, Louis E. Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis. World J Gastroenterol. 2014; 20:4811–4816.
crossref
37. Shaer AJ, Stewart LR, Cheek DE, Hurray D, Self SE. IgA antiglomerular basement membrane nephritis associated with Crohn's disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am J Kidney Dis. 2003; 41:1097–1109.
crossref
38. Plaisier E, Borradori L, Hellmark T, et al. Anti-glomerular basement membrane nephritis and bullous pemphigoid caused by distinct anti-alpha 3(IV)NC1 and anti-BP180 antibodies in a patient with Crohn's disease. Am J Kidney Dis. 2002; 40:649–654.
39. Marques da Costa P, Correia L, Correia LA. The complexity of renal involvment in IBD-C3 glomerulopathy in ulcerative colitis. Inflamm Bowel Dis. 2018; 24:e4–e5.
crossref
40. Pouria S, Barratt J. Secondary IgA nephropathy. Semin Nephrol. 2008; 28:27–37.
crossref
41. Wang J, Anders RA, Wu Q, et al. Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest. 2004; 113:826–835.
crossref
42. Efstratiadis G, Mainas A, Leontsini M. Renal amyloidosis complicating Crohn's disease. Case report and review of the literature. J Clin Gastroenterol. 1996; 22:308–310.
43. Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol. 2008; 103:776–787.
crossref
44. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001; 7:295–300.
crossref
45. Tosca Cuquerella J, Bosca-Watts MM, Anton Ausejo R, Tejedor Alonso S, Mora De Miguel F, Minguez Perez M. Amyloidosis in inflammatory bowel disease: a systematic review of epidemiology, clinical features, and treatment. J Crohns Colitis. 2016; 10:1245–1253.
crossref
46. Cabezuelo JB, Egea JP, Ramos F, Torrella E, Muray S, Alcázar C. Infliximab in the treatment of amyloidosis secondary to Crohn's disease. Nefrologia. 2012; 32:385–388.
47. Iñarrairaegui Bastarrica M, Arín Letamendia A, Zozaya Urmeneta JM, et al. Inflammatory bowel disease and amyloidosis. Gastroenterol Hepatol. 2004; 27:260–263.
48. Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn's disease treated with infliximab. Inflamm Bowel Dis. 2008; 14:431–432.
crossref
49. Pukitis A, Zake T, Groma V, Ostrovskis E, Skuja S, Pokrotnieks J. Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn's disease: case report and review of the literature. J Gastrointestin Liver Dis. 2013; 22:333–336.
50. Blackmur JP, Chapman FA, Bellamy CO, et al. Anti-TNF-α therapy for renal amyloid as a complication of Crohn's disease. QJM. 2014; 107:57–59.
crossref
51. Itano S, Nagayama I, Yamaguchi Y, et al. A case of drug-induced granulomatous interstitial nephritis during the long course of Crohn's disease. Nihon Jinzo Gakkai Shi. 2013; 55:167–171.
52. Tadic M, Grgurevic I, Scukanec-Spoljar M, et al. Acute interstitial nephritis due to mesalazine. Nephrology (Carlton). 2005; 10:103–105.
53. Margetts PJ, Churchill DN, Alexopoulou I. Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. J Clin Gastroenterol. 2001; 32:176–178.
crossref
54. Agharazii M, Marcotte J, Boucher D, Noël R, Lebel M. Chronic interstitial nephritis due to 5-aminosalicylic acid. Am J Nephrol. 1999; 19:373–376.
crossref
55. De Broe ME, Stolear JC, Nouwen EJ, Elseviers MM. 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link? Nephrol Dial Transplant. 1997; 12:1839–1841.
56. Witte T, Olbricht CJ, Koch KM. Interstitial nephritis associated with 5-aminosalicylic acid. Nephron. 1994; 67:481–482.
57. Manenti L, De Rosa A, Buzio C. Mesalazine-associated interstitial nephritis: twice in the same patient. Nephrol Dial Transplant. 1997; 12:2031.
crossref
58. Bailly E, Von Tokarski F, Beau-Salinas F, et al. Interstitial nephritis secondary to vedolizumab treatment in Crohn disease and safe rechallenge using steroids: a case report. Am J Kidney Dis. 2018; 71:142–145.
crossref
59. Izzedine H, Simon J, Piette AM, et al. Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology. 2002; 123:1436–1440.
crossref
60. Marcus SB, Brown JB, Melin-Aldana H, Strople JA. Tubulointerstitial nephritis: an extraintestinal manifestation of Crohn disease in children. J Pediatr Gastroenterol Nutr. 2008; 46:338–341.
crossref
61. Waters AM, Zachos M, Herzenberg AM, Harvey E, Rosenblum ND. Tubulointerstitial nephritis as an extraintestinal manifestation of Crohn's disease. Nat Clin Pract Nephrol. 2008; 4:693–697.
crossref
62. Tokuyama H, Wakino S, Konishi K, Hashiguchi A, Hayashi K, Itoh H. Acute interstitial nephritis associated with ulcerative colitis. Clin Exp Nephrol. 2010; 14:483–486.
crossref
63. Shahrani Muhammad HS, Peters C, Casserly LF, Dorman AM, Watts M. Relapsing tubulointerstitial nephritis in an adolescent with inflammatory bowel disease without aminosalicylate exposure. Clin Nephrol. 2010; 73:250–252.
64. Tovbin D, Kachko L, Hilzenrat N. Severe interstitial nephritis in a patient with renal amyloidosis and exacerbation of Crohn's disease. Clin Nephrol. 2000; 53:147–151.
65. Colvin RB, Traum AZ, Taheri D, Jafari M, Dolatkhah S. Granulomatous interstitial nephritis as a manifestation of Crohn disease. Arch Pathol Lab Med. 2014; 138:125–127.
crossref
66. Timmermans SA, Christiaans MH, Abdul-Hamid MA, Stifft F, Damoiseaux JG, van Paassen P. Granulomatous interstitial nephritis and Crohn's disease. Clin Kidney J. 2016; 9:556–559.
crossref
67. Lewis B, Mukewar S, Lopez R, Brzezinski A, Hall P, Shen B. Frequency and risk factors of renal insufficiency in inflammatory bowel disease inpatients. Inflamm Bowel Dis. 2013; 19:1846–1851.
crossref
68. Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007; 13:629–638.
69. Elseviers MM, D'Haens G, Lerebours E, et al. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin Nephrol. 2004; 61:83–89.
crossref
70. Heap GA, So K, Weedon M, et al. Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease. J Crohns Colitis. 2016; 10:149–158.
crossref
71. Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2000; 14:1–6.
crossref
72. World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant. 1996; 11:614–621.
crossref
73. Calviño J, Romero R, Pintos E, et al. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin Nephrol. 1998; 49:265–267.
74. Oikonomou KA, Kapsoritakis AN, Stefanidis I, Potamianos SP. Drug-induced nephrotoxicity in inflammatory bowel disease. Nephron Clin Pract. 2011; 119:c89–c96.
crossref
75. Ciarcia R, Damiano S, Florio A, et al. The protective effect of apocynin on cyclosporine a-induced hypertension and nephrotoxicity in rats. J Cell Biochem. 2015; 116:1848–1856.
crossref
76. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol. 2003; 23:465–476.
crossref
77. Sereno J, Rodrigues-Santos P, Vala H, et al. Transition from cyclosporine-induced renal dysfunction to nephrotoxicity in an in vivo rat model. Int J Mol Sci. 2014; 15:8979–8997.
crossref
78. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol. 2006; 101:1048–1056.
crossref
79. den Broeder AA, Assmann KJ, van Riel PL, Wetzels JF. Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. Neth J Med. 2003; 61:137–141.
80. Chin G, Luxton G, Harvey JM. Infliximab and nephrotic syndrome. Nephrol Dial Transplant. 2005; 20:2824–2826.
crossref
81. Saint Marcoux B, De Bandt M. CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006; 73:710–713.
82. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007; 86:242–251.
83. Kim Y, Matsushita K, Sang Y, et al. Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis. 2015; 65:550–558.
crossref
84. Waugh J, Hooper R, Lamb E, et al. Spot protein-creatinine ratio and spot albumin-creatinine ratio in the assessment of pre-eclampsia: a diagnostic accuracy study with decision-analytic model-based economic evaluation and acceptability analysis. Health Technol Assess. 2017; 21:1–90.
crossref
85. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63:713–735.
crossref
86. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014; 192:316–324.
crossref
TOOLS
ORCID iDs

Yeonsoon Jung
https://orcid.org/0000-0003-3657-7082

Similar articles